- CD8+Tregs are non-cytotoxic and display a unique and highly immunosuppressive mechanism of action
- CD8+Tregs could be integrated in TxCell’s platforms to offer a different and complementary approach to treat inflammatory and autoimmune disorders
Valbonne, France, and Nantes, France, December 8, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, today announce the signature of an exclusive worldwide licensing agreement. As per the terms of this agreement, TxCell has been granted an exclusive worldwide license to two patent families filed by the Center for Research in Transplantation and Immunology (CRTI), a center of excellence in the field of transplantation and immunology. The CRTI is a research unit (UMR 1064) affiliated to both Inserm, a French public organization dedicated to human health, and to the Nantes University (Nantes, France).